| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
1D09C3 (2.5 µg/mL, 24 h) significantly reduced cell count and cell viability in HLA-DR+ cell lines, but had no effect on HLA-DR- cell lines [1][2]. 1D09C3 (0.1–10 µg/mL, 4–24 h) induced potent time- and dose-dependent cell death in JVM-2 and GRANTA-519 cells [1]. 1D09C3 (10 µg/mL, 4–24 h) induced apoptosis in JVM-2 and GRANTA-519 cells via a caspase-independent pathway [1]. 1D09C3 (10 µg/mL, 5–240 min) induced mitochondrial depolarization and reactive oxygen species (ROS) production in JVM-2 and GRANTA-519 cells [1]. 1D09C3 (10 µg/mL, 0.5–4 h) induces cell death by activating JNK [1]. 1D09C3 (2.5 µg/mL, 4 h) induces B-CLL cell death [1][3]. 1D09C3 (10 µg/mL, 48 h) reduces the number of activated T cells by 20% and the number of resting and activated B cells by 50% [1].
|
|---|---|
| ln Vivo |
1D09C3 (0.01-6 mg/mouse, intravenous injection) significantly improved the overall survival and median survival of mouse models with xenografted JVM-2 cells and GRANTA-519 cells [1].
|
| Animal Protocol |
Animal/Disease Models:JVM-2 (1 x 106) cell xenograft mouse model (NOD/SCID mice, 6-8 weeks) [1]
Doses: 0.01 mg/mouse (day 4), 0.1 mg/mouse (day 4) Route of Administration: Intravenous injection Experimental Results: Overall survival was 20%, and median survival was 64 days. Animal/Disease Models:JVM-2 (0.25 x 106) cell xenograft mouse model (NOD/SCID mice, 6-8 weeks) [1] Doses: Early disease treatment: 1 mg per mouse on days 4, 7, and 9, for a total of 3 times; 1 mg per mouse on day 4; Late disease treatment: 1 mg per mouse every 48 hours starting from day 15, for a total of 6 times. Route of Administration: Intravenous injection Experimental Experimental Results: At doses up to 3 mg/mouse, the survival rate was 100%; the overall survival rate was 42%, and the median survival time was 99 days. Animal/Disease Models:GRANTA-519 and KMS-11 cell xenograft mouse models (NOD/SCID mice, 6-8 weeks old) [1][2][3] Doses: Early disease treatment: 1 mg per mouse on days 1, 4, and 7, for a total of 3 doses; Late disease treatment: 1 mg per mouse starting from day 7, for a total of 6 doses, with each dose spaced 48 hours apart. Route of Administration: Intravenous injection Experimental Results: Significantly prolonged median survival (108 days), with 27% of mice surviving and disease-free at the end of the 120-day observation period. |
| References |
|
| CAS # |
791073-97-7
|
|---|---|
| Appearance |
Typically exists as solids at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
